2016 CLLSA Glasgow Members Conference

 

CLL SUPPORT ASSOCIATION

Monday 19 September 2016

10:00am – 4:00pm

The Grand Central Hotel, 99 Gordon Street,

Glasgow, G1 3SL

PROGRAMME

 

There were 4 medical presentations: two given by

Dr Alison McCraig Affiliate (Paul O'Gorman Leukaemia Research Centre) Glasgow University

as well as presentations by

Dr Emilio Cosimo Research Associate (Paul O'Gorman Leukaemia Research Centre) Glasgow University

Dr Ailsa Holroyd Clinical Research Fellow (Institute of Cancer Sciences) Glasgow University. Three patients also gave their story

 

Presentation 1: Dr Alison McCraig

Affiliate (Paul O'Gorman Leukaemia Research Centre) Glasgow University

An overview of CLL from Diagnosis through to treatment.

This presentation gives an overview of CLL from diagnosis, through clinical symptoms and complications, staging, indications for treatment and the pathogenesis of CLL.

Highlights the CLL microenvironment influences B cell survival and introduces Cytogenetics chromosome abnormalities and the clinical implications of somatic mutations and their effect on treatment.

A quick timeline for the development of CLL therapy follows. The presentation is wrapped up with an introduction to the gold standard therapy FCR and a look at what the limitations of FCR are.

 

Presentation 2: Dr Alison McCraig

Affiliate (Paul O'Gorman Leukaemia Research Centre) Glasgow University

An overview CLL Therapy Past, Present, Future.

In this presentation Dr Alison McCraig looks at the challenges that need to be addressed: more effective treatments less toxic, preferably oral, and identify patients who will not respond well to current treatments

Treatments reviewed:
Other Chemotherapy agents (Bendamustine)
Newer Anti-bodies (Ofatumumab, Obinutuzumab)
B cell receptor signalling inhibitors (Idelalisib and Ibrutinib)
Bcl-2 antagonist (Venetoclax)

Treatment considerations and what treatments are approved and in use in Scotland are covered.

The challenge now is to determine optimum combination of current therapies and novel agents

It is hoped that the results of current clinical trials will answer the questions raised by the new therapies and lead to improvements in the lives of patients with CLL.

 

 

Presentation 3: Dr Emilio Cosimo

Research Associate (Paul O'Gorman Leukaemia Research Centre) Glasgow University

Developing new treatments for CLL – an insight into the lab.

CLL is a disease of uncontrolled proliferation. Proliferation centres which are within the lymph nodes and bone marrow provide protective signals which enables CLL cells to survive, proliferate and repopulate the blood. CLL cells depend on interactions with microenvironment for their survival.

The talk covers research into how AZD-8055 inhibits cell proliferation.
 

 

 

Presentation 4: Dr Ailsa Holroyd

Clinical Research Fellow (Institute of Cancer Sciences) Glasgow University

Dr Ailsa Holroyd presents some of her research into BCR signalling and the functional impact of mTor kinase inhibitors on BCR signalling.

Showing results of in vitro and in vivo experiments to better understand whether mTor kinase inhibitors like AZD-8055 can be used to improve therapy

 

Patient Presentations:

 

Hugh, Derek and Brian also gave their stories